Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) FCF Margin (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed FCF Margin for 14 consecutive years, with 63.62% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 8702.0% year-over-year to 63.62%, compared with a TTM value of 27.57% through Dec 2025, up 11732.0%, and an annual FY2025 reading of 49.24%, up 9375.0% over the prior year.
  • FCF Margin was 63.62% for Q4 2025 at Enanta Pharmaceuticals, down from 52.54% in the prior quarter.
  • Across five years, FCF Margin topped out at 94.74% in Q2 2025 and bottomed at 177.49% in Q1 2024.
  • Average FCF Margin over 5 years is 104.64%, with a median of 121.91% recorded in 2021.
  • The sharpest move saw FCF Margin plummeted -11739bps in 2022, then skyrocketed 19900bps in 2025.
  • Year by year, FCF Margin stood at 49.31% in 2021, then crashed by -216bps to 155.69% in 2022, then increased by 8bps to 143.17% in 2023, then fell by -5bps to 150.63% in 2024, then surged by 58bps to 63.62% in 2025.
  • Business Quant data shows FCF Margin for ENTA at 63.62% in Q4 2025, 52.54% in Q3 2025, and 94.74% in Q2 2025.